The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy

Affiliations

Comment

Saiama N Waqar et al. JAMA Oncol. 2020.

. 2020 May 1;6(5):674-675.

doi: 10.1001/jamaoncol.2020.0264.

¹ Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO.

No abstract available

Comment in

Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection-Reply.
Waqar SN, Govindan R. Waqar SN, et al. JAMA Oncol. 2020 Nov 1;6(11):1809-1810. doi: 10.1001/jamaoncol.2020.3397. JAMA Oncol. 2020. PMID: 32880608 No abstract available.
Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection.
Fabrizio DA, Hegde P, Alexander B. Fabrizio DA, et al. JAMA Oncol. 2020 Nov 1;6(11):1808-1809. doi: 10.1001/jamaoncol.2020.3386. JAMA Oncol. 2020. PMID: 32880611 No abstract available.

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Rizvi NA, et al. JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237. JAMA Oncol. 2020. PMID: 32271377 Free PMC article. Clinical Trial.